Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H14ClNO2 |
Molecular Weight | 251.709 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC(Cl)=C(C=C1)N2CC=CC2
InChI
InChIKey=PIDSZXPFGCURGN-UHFFFAOYSA-N
InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
Molecular Formula | C13H14ClNO2 |
Molecular Weight | 251.709 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Pirprofen is a non-steroidal anti-inflammatory drug, related structurally to drugs such as ibuprofen, ketoprofen and naproxen. Pirprofen was introduced by Ciba-Geigy in 1982 as a treatment for rheumatic diseases. In 1990 due to adverse effects, including some cases of fatal liver toxicity the manufacturers decided to discontinue marketing it worldwide. Pirprofen proved to be useful in the management of both rheumatoid arthritis and osteoarthritis and as an analgesic. In doses of 600-800 mg/d, pirprofen has been found to be as effective as, but not superior to, aspirin 3.6 g/d in relieving the more common symptoms of rheumatoid arthritis. Pirprofen is as effective as, but not superior to, other available NSAIDs in terms of efficacy, tolerability, and incidence of adverse effects. The recommended dosage in osteoarthritis is 450-600 mg/d.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3539573
Published clinical trials indicate that pirprofen 600 to 1200 mg/day as 2 or 3 divided doses is a suitable alternative to usual therapeutic dosages of aspirin, flurbiprofen, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam and sulindac in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders and non-articular rheumatism. In patients with acute postsurgical, trauma or cancer pain, single oral or intramuscular doses of pirprofen 200 to 400mg provide equivalent analgesic activity to usual therapeutic doses of aspirin, diflunisal, ketoprofen, noramidopyrine, paracetamol and pentazocine.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/804924
Curator's Comment: Pirprofen, racemic 2-[3-chloro-4(3-pyrrolinyl) phenyl] propionic acid, was evaluated for its ability to inhibit the conversion of arachidonic acid into prostaglandin E2 by sheep seminal vesicle prostaglandin synthase in vitro.
The compound proved to be a potent inhibitor with a Ki value of about 1.2 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:15:04 GMT 2023
by
admin
on
Fri Dec 15 17:15:04 GMT 2023
|
Record UNII |
T7KN291890
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AE08
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
||
|
WHO-ATC |
M01AE08
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
35935
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
C008924
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
Pirprofen
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
m896
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
2213
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
T7KN291890
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
DTXSID7023489
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
3717
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
31793-07-4
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
250-805-8
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
46801-03-0
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
SUPERSEDED | |||
|
C170327
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
DB13722
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
SUB09940MIG
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL188952
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY | |||
|
100000081700
Created by
admin on Fri Dec 15 17:15:04 GMT 2023 , Edited by admin on Fri Dec 15 17:15:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |